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EIAThis study evaluated the reactivity of membrane antigens of Leishmania (Viannia) braziliensis for the diagnosis
of ACL by enzyme immunoassay (EIA). Promastigotes of L. (V.) braziliensis were grown in medium 199 and
lysed in a sonicator. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blotting showed that speciﬁc proteins of L. (V.) braziliensis (apparent molecular weights 36 kDa and 48–56
kDa) were recognized by sera from ACL patients. These proteins were eluted from the SDS-PAGE and tested in
EIA-IgG with sera from ACL patients, healthy individuals, patients with toxoplasmosis, paracoccidioidomy-
cosis, syphilis, tuberculosis, leprosy, and Chagas disease. The EIA-IgG with membrane antigens allowed us to
distinguish patients with ACL from healthy individuals and patients with other diseases (P b 0.0001), and
showed a sensitivity of 93.3% and speciﬁcity of 90.8%, not including Chagas disease patients. 2D-SDS-PAGE
followed by Western blotting was performed to improve the characterization of the antigens, and showed a
component with isoelectric points near the acid pH side and apparent molecular weights of 48–56 kDa. The
results showed good sensitivity and speciﬁcity of EIA-IgG with membrane antigens, indicating their potential
use for diagnosis of ACL, as well as seroepidemiological surveys and follow-up of clinically cured patients.+55-44-3011-4860.
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Cutaneous leishmaniasis affects about 12 million people world-
wide (except countries of Oceania) with 1.5 million new cases
annually, and it is estimated that over 350 million people live in risk
areas. Despite advances in the treatment, diagnosis, and prevention of
leishmaniasis over the past 10 years, morbidity and mortality caused
by this disease still concern health authorities (WHO, 2010).
In the Americas, American cutaneous leishmaniasis (ACL) occurs
from the southern United States to northern Argentina, except Chile
and Uruguay. In Brazil, ACL is caused by species of the subgenera
Viannia and Leishmania (Brasil, 2007) and manifests itself by
cutaneous and mucocutaneous lesions; recent decades have seen an
increasing number of cases and extension of the ACL geographical
distribution. ACL is currently found in all Brazilian states, under
different epidemiological proﬁles (Basano and Camargo, 2004). From
1990 to 2010, the great majority of the 12,837 cases reported for thesouthern region occurred in Paraná State, totaling 12,187 events
(Brasil, 2011a) with an annual incidence of 6.5 new cases/100
thousand inhabitants (Brasil, 2011b), mainly in 276 of the 399
municipalities in the state (Lima et al., 2002).
ACL is diagnosed based on epidemiological, clinical, and laboratory
criteria, and often a combination of these is needed to reach the ﬁnal
diagnosis. Gontijo and Carvalho (2003) noted that, although clinical
and epidemiological data may suggest the possibility of leishmaniasis,
only deﬁnitive identiﬁcation of the parasite can conﬁrm the diagnosis.
Laboratory diagnosis of ACL is accomplished through a group of
parasitological and immunological tests, with the combination of
three techniques, as recommended by the BrazilianMinistry of Health
regulations (Brasil, 2007): direct search for Leishmania sp. in the
lesion (DS), Montenegro's skin test (MST) and the indirect immuno-
ﬂuorescence test (IIF). The IIF can be used for laboratorymonitoring of
patients after treatment (Brasil, 2007, Chiari et al., 1973).
Direct search for the parasite in a lesion is rapid, low-cost, and easy
to implement, but has low sensitivity (50–70%); in contrast, the use of
polymerase chain reaction to detect leishmanial DNA in specimens
from skin lesions provides good sensitivity and speciﬁcity (Vega-
Lopez, 2003). The parasite load in the lesion decreases as the lesion
progresses (Gontijo and Carvalho, 2003; Andrade et al., 2005).
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delayed hypersensitivity of the individual. It has good clinical
applicability, low cost, and high positivity, which are important assets
in the diagnosis of cases in which the parasites are scarce or absent in a
lesion, as well as in epidemiological studies in endemic areas (Shaw and
Lainson, 1975). However, cross-reactions can occur with other diseases
(Chagas disease, sporotrichosis, tuberculosis, etc.), i.e., the technique has
low speciﬁcity (Medeiros et al., 2002; Brasil, 2007). Positivity can persist
for years after clinical cure, invalidating its use for diagnosis of a current
lesion in individuals who have already had the disease (Weigle et al.,
2002). Also, some patients are allergic to the test diluent (Fagundes et
al., 2007).
The IIF is a sensitive serological method. However, there is the
possibility of cross reactions, especially with Trypanosoma cruzi
(Kar, 1995). This test can give variable results for ACL, due to
reduced antigenicity of the parasite or to low levels of circulating
antibodies. In patients with cutaneous lesions, the sensitivity of IIF
is estimated at 71% (Mendonça et al., 1988). Antibody titers are
high in patients with multiple lesions (Gontijo and Carvalho,
2003). In addition, the reactions tend to be negative in the
beginning of the infection (1–3 months), unlike direct search,
which tends to be positive (Chiari et al., 1973). After treatment
and clinical cure, the titers may fall or disappear in a few months
(Gontijo and Carvalho, 2003).
The enzyme immunoassay (EIA) has been used because it is more
sensitive and faster. EIA tests using crude, puriﬁed, or recombinant
antigens of Leishmania have shown sensitivity rates ranging from85% to
100% (Barroso-Freitas et al., 2009; Junqueira-Pedras et al., 2003; Vidigal
et al., 2008; Yoneyama et al., 2007). Antigenic fractions of promastigotes
of Leishmania (Viannia) braziliensis were puriﬁed and showed good
speciﬁcity and sensitivity in the diagnosis of ACL, by Western blotting
tests (Vidigal et al., 2008) and EIA (Cataldo et al., 2010; Gomes-Silva et
al., 2008; Ryan et al., 2002; Vidigal et al., 2008; Yoneyama et al., 2007).
The present study evaluated an EIA using membrane proteins of L. (V.)
braziliensis as the antigen for the diagnosis of ACL.2. Materials and methods
2.1. Patients and sera
To evaluate the diagnostic performance indexes of the test with
the membrane antigens, a total of 221 serum samples were used:
60 from patients with ACL (positive DS) who were treated at the
Laboratory for Teaching and Research in Clinical Analysis of the
State University of Maringá (LEPAC/UEM), referred by the 15th
Regional Health Authority of the State of Paraná; 66 from healthy
individuals with no history of ACL; 57 for Chagas disease (positive
IIF-IgG); and 54 from individuals with positive serology for other
diseases [10 for acute toxoplasmosis (presence of IgG and IgM, by
EIA; Abbott Laboratories), 10 for chronic toxoplasmosis (presence
of IgG by EIA; Abbott Laboratories), 11 for syphilis (positive by the
FTA-Abs test; BioMerieux), 7 for paracoccidioidomycosis (positive
immunodiffusion), 10 for tuberculosis (positive acid-fast bacillus
sputum and chest X-ray) and 6 for leprosy (positive clinical
examination and earlobe smear)].
To evaluate the test performance, we analyzed 85 serum samples,
belonging to patients with cutaneous lesions (suspicious of the
cutaneous form of ACL) and 19 from patients with mucosal lesions
(suspicious of the mucosal form of ACL). These patients were
referred to the LEPAC/UEM for laboratory diagnosis of ACL during
the 2010–2011 period. All serum samples were stored at −30 °C
until use.
This study was approved by the Permanent Committee for Ethics
in Research Involving Humans of the State University of Maringá
(report 294/2006).2.2. Obtaining the membrane antigens
Promastigote forms of L. (V.) braziliensis (MHOM/BR/1987/M11272)
were cultured at 25 °C in culture medium 199 (Gibco, Invitrogen, NY,
USA) with antibiotics (penicillin G 100 UI/mL, streptomycin 100 μg/mL,
Sigma-Aldrich, Saint Louis, MO, USA), supplemented with 10% fetal calf
serum(Gibco, Invitrogen, NY, USA), 1% of 20mmol/L L-glutamine (Sigma-
Aldrich, Saint Louis, MO, USA) and 1% sterile human urine, until the
exponential growth phase. The parasites were washed 3 times with
phosphate-buffered saline (PBS) pH 7.2 (193 g, 20 min, 4 °C), counted,
protease inhibitors were added (100 mg/mL of PMSF, Gibco), and the
parasites were stored at −18 °C until use. The antigen was prepared
according to Saha et al. (2005), with modiﬁcations. Aliquots of frozen
parasiteswere resuspended in 5mmol/L Tris–HCl, pH 7.6, and agitated on
a vortex mixer (6 cycles of 2 min with intervals of 10 min) in an ice bath.
Thematerialwas centrifuged (2300g, 20min, 4 °C), the supernatantwas
discarded and the pellet resuspended in 10 mL of Tris–HCl, maintained
in an ice bath, stirred on a vortex mixer (3 cycles, 1 min) and then
sonicated (3 cycles, 20 KHz, 1 min), centrifuged (5200 g, 20 min, 4 °C),
and the supernatant was aliquoted and stored at−30 °C. The proteins
were measured by the spectrophotometric method using a Quanti-It
Protein Assay kit (Invitrogen, Eugene, OR, USA).
2.3. Polyacrylamide gel electrophoresis (SDS-PAGE)
Themembrane antigens were diluted in sample buffer (0.123mol/
L Tris–HCl, pH 6.8, 0.139 mol/L SDS, 2.17 mol/L glycerol, 0.005%
bromophenol blue and 0.005% pyronin y) with 10% 2-mercaptoetha-
nol and Tris–HCl 5 mmol/L, pH 7.6, and submitted to electrophoresis
on 10% polyacrylamide gels in a mini-gel apparatus (Hoefer, San
Francisco, CA, USA) at 100 V and 30 mA for approximately 5 h
(Laemmli, 1970). The molecular weight marker used was the
Benchmark Prestained Protein Ladder (Invitrogen, Carlsbad, CA, USA).
After electrophoresis, the membrane antigens were transferred to
nitrocellulose membrane and the reactivity was analyzed by Western
blotting. Alternatively, the gels were stained with silver according to
Blumm et al. (1987) for visualization of the protein bands, or eluted to
obtain the proteins of interest.
2.4. Two-dimensional polyacrylamide gel electrophoresis
(2D-SDS-PAGE)
A total of 2 mL of sample containing peptides with apparent
molecular weights of 36 kDa and 56–48 kDa (previously separated
by elution of the gel, as described in item 2.6) was precipitated with
4 volumes of cold acetone according to the Technical Information
Bulletin of Thermo Scientiﬁc. The proteins were solubilized in 100 μL
of 7 mol/L urea, 2 mol/L thiourea, 4% CHAPS and 40 mmol/L DTT
buffer, prepared for isoelectric focalization with a 2D Clean-Up kit
(GE Healthcare Bio-Science AB, Piscataway, MA, USA) and resus-
pended in 250 μL hydration buffer (7 mol/L urea, 2 mol/L thiourea,
4% w/v CHAPS, 0.002% bromophenol blue). Protein concentrations
were determined using the Bradford assay, and the amount of
protein used in the analysis was 15 μg. Before isoelectric focalization,
40 mmol/L DTT and 0.5% IPG Buffer were added and the proteins
were then applied to Immobiline DryStrip gels, pH 3 to 10 (13 cm,
GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Isoelectric
focusing was performed in the IPG-phor II IEF System (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) at 20 °C, 500 V for
1 h, 1000 V for 1 h, 8000 V for 2 h 30 min, and 8000 V for 30 min.
Subsequent to the ﬁrst dimension, and before loading onto SDS-
PAGE gels, IPG strips were equilibrated in 6 mol/L urea, 2% SDS, 29.3%
glycerol, 75 mmol/L Tris–HCl, pH 8.8, and 0.002% bromophenol blue,
reduced with 1% DTT, and alkylated with 2.5% iodoacetamide.
The equilibrated strips were overlaid on homogeneous 12%
polyacrylamide SDS-PAGE gels (1.0 mm thick), and the
Fig. 1. Western blotting of membrane proteins (36 μg/lane) from promastigotes of
Leishmania (Viannia) braziliensis. The reactivity of proteins was analyzed with sera from
ACL patients (lanes 1–7: positive direct search and different titer of IIF-IgG). Each lane
represents one serum. The molecular weight (MW; Benchmark Prestained Protein
Ladder, Invitrogen) is on the left. On the right, the apparent molecular weights of new
bands are marked.
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then 300 V, 50 mA for 4 h using a Hoefer SE 600 Ruby electrophoresis
unit (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) at 15°C with
12 μL of ColorPlus Prestained Protein Ladder (New England Biolabs,
Beverly, MA, USA). Proteins were detected by a modiﬁed Neuhoff Blue
Silver Coomassie Colloidal Blue staining protocol followed by silver
staining. After 2D electrophoresis, the gel was ﬁxed in 5% acetic acid
and documented using the software LabImage 1D (Loccus
Biotechnology).
Alternatively, the antigens were transferred from 2D-SDS-PAGE
to nitrocellulose membrane and the reactivity was analyzed by
Western blotting.
2.5. Western blotting
The transfer of proteins in polyacrylamide gels to nitrocellulose
membrane was carried out in an electrotransfer apparatus (Hoefer,
San Francisco, CA, USA) at 30 V and 150mA, overnight. Themembrane
was blocked with PBS containing 10% skimmilk for 2 h under shaking.
Subsequently, the membrane was incubated for 2 h with human
serum diluted 1/50 in PBS and then with anti-human IgG conjugated
to biotin (Sigma-Aldrich) (1/1000) in PBS for 2 h under shaking. Then,
the nitrocellulose membrane was incubated with streptavidin-
peroxidase (Zymed, San Francisco, CA, USA) (1/1000) in PBS with
shaking in the dark. The reactive band was revealed with 4-chloro-2-
naphthol (Sigma-Aldrich) (0.5 mg/mL in 0.04 mol/L Tris pH 7.0
containing 0.18 mol/L NaCl and 0.1% H2O2). The reaction was stopped
by washing the membrane with distilled water.
2.6. Elution of proteins from gels
For elution of the proteins of interest, the gel was cut into strips
with a steel spatula previously cleaned with 70% ethanol, according to
the pattern of molecular weight. The gel pieces were placed in sterile
syringes, coupled to the ﬁlter membrane with pores of 3 μmwith 1 mL
carbonate-bicarbonate buffer, pH 9.6. The ﬁltrate was stored at−30 °C
until use.
2.7. Enzyme immunoassay (EIA-IgG)
The reactivity of fractions and the appropriate concentration were
determined by titration, using sera from ACL patients and healthy
individuals.
Polystyrene plates of 96 wells (Nunc-Immuno Plate Maxisorp
Surface, Denmark) were coated with 50 μL of antigen solution (3 μg of
protein) per well, diluted in carbonate-bicarbonate buffer, pH 9.6, and
incubated overnight at 4 °C. The plates were washed with PBS and
blocked with 200 μL of 1% bovine albumin (Gibco, Invitrogen
Corporation, NY, USA) in PBS [1% bovine serum albumin (BSA)] and
washed againwith PBS. The serum samples (100 μL) diluted 1/150 in 1%
BSA were added to each well. The plate was incubated for 2 h at 25 °C
and washed. Conjugated anti-human IgG-peroxidase (Sigma-Aldrich)
(1/1000) in BSA was added (100 μL per well). After 2 h of incubation at
25 °C, the plate was washed with PBS. The reaction was revealed with
100 μL of OPD (o-phenylenediamine-2HCl, Sigma-Aldrich) 1 mg/mL in
0.05 mol/L phosphate-citrate, pH 5.0 containing 0.03% H2O2 for 15 min
at 25 °C. The reaction was stopped with 50 μL of 3 mol/L H2SO4.
Absorbance was measured with a microplate reader (ASYS microplate
reader v1.4, Eugendorf, Austria) at 492 nm with a 620 nm reference
ﬁlter. All serum samples were analyzed in duplicate.
2.8. Data analysis
Standard diagnostic indexes including sensitivity, speciﬁcity,
positive predictive value, negative predictive value, and Cohen'sKappa index of the EIA-IgG were calculated using OpenEpi
2.3.1 software.
Themean reactivity of groups, conﬁdence intervals, and the groups
were compared by Student's t test, using GraphPad Prism Software
version 5.0, with signiﬁcance level P b 0.05.
3. Results
The reactivity of membrane antigens was analyzed by Western
blotting using sera from patients with ACL (positive DS and IIF-IgG),
patients with Chagas disease and healthy individuals. Components of
apparentmolecular weights of 11, 36, and 56–48 kDawere recognized
by all sera from ACL patients (Fig. 1), 2 of 7 sera from Chagas disease
patients, and none from healthy individuals tested (data not shown).
Subsequently, the reactivity of the protein fractions observed in the
nitrocellulose membrane and eluted from the gel (11, 36, 48–56 kDa)
was analyzed with sera from patients with ACL and Chagas disease and
healthy individuals by EIA-IgG (Fig. 2). The best discrimination of these
serawas obtained bymixing theprotein fractions of apparentmolecular
weights 36 kDa and 48–56 kDa. The third component isolated (11 kDa)
did not produce good results, either alone or in conjunction with the
other two. The optimal concentration of antigen was determined by
titration using ACL and healthy sera and established at 3 μg of protein
per well (1.5 μg of each protein fraction; 36 and 48–56 kDa).
Sera from 60 patients with ACL (positive DS), 66 healthy
individuals (no history of ACL), 57 with Chagas disease, and 54
patients with other diseases (syphilis, acute and chronic toxoplas-
mosis, paracoccidioidomycosis, tuberculosis, and leprosy) were tested
by EIA-IgG (Fig. 3).
Table 1 shows the difference in average reactivity between groups
of patients with ACL or other diseases and healthy patients (P b 0.001).
However, no signiﬁcant difference between groups of patients with
ACL and Chagas disease was found (P = 0.193). Furthermore, there
was no difference between the groups of healthy sera and the group of
other diseases (P = 0.50).
Fig. 2. Reactivity of fractions eluted from the SDS-PAGE. The reactivity of different fractions eluted from the SDS-PAGE with sera was analyzed by EIA-IgG.
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sera plus 2 standard deviations. The EIA-IgG was validated using this
cutoff according to the criteria for sensitivity, speciﬁcity, and positive
and negative predictive values. The sensitivity was 93.3% and
speciﬁcity was 95.5% in healthy individuals. In the group of patients
with other diseases, false positives were detected in the group with
acute toxoplasmosis (1/10) with syphilis (1/10), with tuberculosis (4/
10) and with leprosy (2/6), and were not detected in the group withACL H CD PCM AT
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Fig. 3. Reactivity of the membrane antigen from L. (V.) braziliensis,with different groups of s
fractions) and sera (diluted at 1/150) of patients with cutaneous leishmaniasis (ACL), health
chronic toxoplasmosis (CT), syphilis (SY), tuberculosis (TB) and leprosy (LE). Each symbol re
solid horizontal line, in each group, represents the mean absorbance of the sera group. “N”paracoccidioidomycosis (0/7). The test showed low speciﬁcity for the
Chagas disease group, detecting 44 of 57 sera. Including the healthy
individuals and individuals with other diseases (non-Chagas disease),
the speciﬁcity and positive and negative predictive values were 90.8%,
83.6%, and 96.5%, respectively (Table 2). Fig. 4 shows the receiver
operating characteristic (ROC) curves, with and without including
patients with Chagas disease, in the performance of the EIA-IgG. The
cutoff chosen was conﬁrmed by the ROC curve.CT SY TB LE
0.54 (mean H+2DP)
(n = 11)(n = 10) (n = 10) (n = 6)
era, by EIA-IgG. EIA-IgG was performed using 3 μg/well of antigens (36- and 48–56-kDa
y (H), Chagas disease (CH), paracoccidioidomycosis (PCM), acute toxoplasmosis (AT),
presents a serum sample. The horizontal lines indicate a possible cutoff value. The short
represents the number of samples.
Table 1
Enzyme immunoassay with sera from patients with American cutaneous leishmaniasis, healthy individuals, other diseases and Chagas disease.
Sera groups Absorbance, mean ± SD Conﬁdence interval of 95% P (ACL vs other sera groups)
American cutaneous leishmaniasis (n = 60) 0.931 ± 0.361 0.838–1.024
Healthy individuals (n = 66) 0.243 ± 0.149 0.206–0.279 b0.001
Other diseases (non-Chagas disease) (n = 54) 0.344 ± 0.177 0.296–0.393 b0.001
Chagas disease (n = 57) 0.835 ± 0.429 0.723–0.949 0.193
Other diseases (with Chagas disease) (n = 111) 0.597 ± 0.412 0.519–0.674 0.002
Healthy individuals and other diseases (non-Chagas disease) (n = 120) 0.287 ± 0.169 0.258–0.319 b0.001
Healthy individuals and other diseases (with Chagas disease) (n = 177) 0.465 ± 0.379 0.409–0.521 b0.001
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compared. The sensitivity of the EIA-IgG was 93.3% (56/60) and of the
IIF-IgG was 88.3% (53/60), and 2 sera groups showed negative results
in the two assays. The agreement was 88.3%, with Cohen's Kappa
index of 0.30, which was used for both methodologies.
To evaluate the performance of the EIA-IgG using membrane
antigens, serum samples from patients who were referred to LEPAC/
UEM for laboratory diagnosis of ACL were analyzed. Table 3 shows the
results for 85 patients with suspected ACL lesions. The EIA-IgG was
positive in 12 of 14 patients who were positive DS (85.7%). Of 7
patients with negative DS, but MST positive, the EIA-IgG was positive
in 4 (57.1%). Of 30 patientswith negative DS andMST, the EIA-IgGwas
negative for 28 (93.3%). Of 31 patients with negative DS and
unrealized MST, the EIA-IgG was positive in 8 (25.8%), indicating
that the causal agent of this lesion is probably L. (V.) braziliensis.
Of 19 serum samples from patients with mucosal lesions, 10
(52.6%) were positive by EIA-IgG. Of the 10 patients with positive
MST, 7 (70%) had positive EIA-IgG, and of 6 with unrealized MST, the
EIA-IgG was positive in 3. All 3 patients with negative MST had
negative EIA-IgG.
2D-SDS-PAGE combined with Western blotting was performed to
enhance the characterization of the membrane antigens. The 2D-SDS-
PAGE conﬁrmed the presence of the same components observed by
1D-SDS-PAGE, with isoelectric points near the acid pH side (Fig. 5A).
The Western blotting assay performed from the 2D-SDS-PAGE
showed reactivity with serum from the ACL patients (positive direct
search and titer 1:320 in the IIF) (Fig. 5B). Reactivity was not observed
in sera from healthy individuals and from a patient with Chagas
disease (titer 1:640 in the IIF) (data not shown).
4. Discussion
American cutaneous leishmaniasis (ACL) is a skin infection that
deserves attention because it produces physical deformities and
consequently psychological problems, with repercussions for the
economic and social life of individuals. ACL is widely distributed
throughout Brazil, with cases reported in all states (Brasil, 2007). In
Paraná State, ACL is endemic in the north and northwest (Curti et al.,
2009; Lima et al., 2002; Silveira et al., 1999).
Investigators have searched for serological techniques that are
more sensitive and speciﬁc, less invasive, less costly, and easy to
perform, with more accurate and puriﬁed antigens. Among theTable 2
Performance of enzyme immunoassay (EIA-IgG) for the diagnosis of American cutaneous le
Sera groups Sensitivity (%)
American cutaneous leishmaniasis 93.3% (56/60)
Healthy individuals
Other diseases (non-Chagas disease)
Chagas disease
Other diseases (with Chagas disease)
Healthy individuals and other diseases (non-Chagas disease)
Healthy individuals and other diseases (with Chagas disease)existing serological tests, EIA seems to be a good choice since it can be
automated, allowing a large number of samples to be analyzed
simultaneously in a relatively short period (Ferreira et al., 2001).
To the best of our knowledge, there is no research using this
membrane proteins extracted from L. (V.) braziliensis. The results of
this study showed that membrane antigens of L. (V.) braziliensis
promastigote forms can be separated, extracted and used in EIA. The
proteins obtained by SDS-PAGE have approximate molecular weights
of 11, 36, and 48–56 kDa. These fractions were recognized by all sera
from ACL patients, by none of the sera from healthy individuals, and
by 2 serum samples from patients with Chagas disease, by Western
blotting. These ﬁndings are consistent with those of Masuda et al.
(1989) who reported bands of 60 kDa of soluble antigen of L. (V)
braziliensis that were recognized by sera from patients with ACL.
However, we did not detect a protein of 72 kDa found by Legrand et al.
(1987) and Kutner et al. (1991), perhaps due to the method of
preparation of the antigen (membrane proteins or total soluble
proteins) or different strains studied.
The results for EIA-IgG with this membrane antigen preparation
showed that sera from patients with ACL are distinct from the sera
from healthy individuals (P b 0.0001) as well as from the sera from
patients with other diseases (P b 0.0001). The sensitivity and speci-
ﬁcity were also good, namely, 93.3% and 90.8%, respectively. Other
studies using soluble antigens of L. (V.) braziliensis found 93% sen-
sitivity and a speciﬁcity of 94.8% (Yoneyama et al., 2007), and antigens
obtained by ﬁltration chromatography (peak II of fraction 8) showed a
sensitivity of 85.4% and speciﬁcity 91.2% (Vidigal et al., 2008).
These results are consistent with the results of Barroso-Freitas et
al. (2009), who worked with soluble antigens of L. (V.) braziliensis
and found sensitivity and speciﬁcity of 95.7% and 100%. Cataldo et al.
(2010) used soluble antigens and membranes enriched with Triton
X-100 and found sensitivity and speciﬁcity of 89.5% and 89.5%
(soluble antigen) and 89.5% and 93.4% (membrane antigen). Another
point to be emphasized is the comparison of EIA and IIF tests that
are currently used. The sensitivity of the EIA-IgG was 93.3%, com-
pared to that of IIF which was 88.3%, in 60 patients with positive
direct search for parasites. Gomes-Silva et al. (2008), working with
soluble antigens isolated from promastigotes of the L. braziliensis
complex, found a sensitivity of 80–95% depending on the type of
antigen puriﬁcation used.
The results of EIA-IgG for the sera from patients with Chagas'
disease showed 77.2% reactivity with the antigen of L. (V.) braziliensisishmaniasis.
Speciﬁcity (%) Predictive value
Positive Negative
95.5% (63/66)
85.2% (46/54)
22.8% (13/57)
53.2% (59/111)
90.8% (109/120) 83.6% (56/67) 96.5% (109/113)
68.9% (122/177) 50.1% (56/111) 96.8% (122/126)
Fig. 4. ROC curves of sera samples analyzed by EIA-IgG using membrane antigens of L. (V.) braziliensis. EIA-IgG was performed using 3 μg/well of antigens (36- and 48–56-kDa
fractions) and sera (diluted 1/150) from patients. (A) Serum samples from patients with cutaneous leishmaniasis, healthy individuals, and with paracoccidioidomycosis, acute
toxoplasmosis, chronic toxoplasmosis, syphilis, tuberculosis and leprosy. (B) Serum samples from patients with cutaneous leishmaniasis, healthy individuals, and with Chagas
disease, paracoccidioidomycosis, acute toxoplasmosis, chronic toxoplasmosis, syphilis, tuberculosis and leprosy.
416 C.M. Skraba et al. / Diagnostic Microbiology and Infectious Disease 78 (2014) 411–417(Vexenat et al., 1996). However, the authors argue that cross-
reactivity among patients with T. cruzi and L. (V.) braziliensis can be
up to 100% in the EIA. Chagas disease is not part of the differential
diagnosis for ACL (Brasil, 2007; Gontijo and Carvalho, 2003), although
in many regions both of these diseases may be present. In these cases,
clinical and epidemiological criteria must be considered.
To evaluate the speciﬁcity of the EIA-IgG, sera were tested from
patients with syphilis (FTA-Abs positive), paracoccidioidomycosis
(positive immunodiffusion) tuberculosis (positive acid-fast bacillus
sputum and chest X-ray), leprosy (positive clinical examination and
earlobe smear), and also in acute toxoplasmosis (IgM/IgG positive)
and in the chronic phase (positive IgG). Only 8 patients (one with
acute toxoplasmosis, one with syphilis, two with leprosy and four
with tuberculosis) were positive for this technique. Thus, excluding
sera from patients with Chagas disease, the speciﬁcity found was
90.8%. The good performance of the EIA-IgG usingmembrane antigens
of L.(V.) braziliensis is shown in the ROC curve.
The EIA-IgG test was used as amethod for serological diagnosis (85
sera from patients with cutaneous lesions and 19 with mucosal
lesions). The positivity was 85.7% in patients with a positive DS (direct
search). Among patients with negative DS and MST, 93.3% were also
negative in the EIA. Yoneyama et al. (2007), using these same
parameters for comparison, found 97.0% positive and 81.8% negativity.
The results of the EIA-IgG of patients with mucosal lesions agreed in
84.2% of results with the IIF, and none of patients with negative MST
was positive in the EIA-IgG. Thus, the antigens used for the diagnosis
of cutaneous leishmaniasis may also be used for the mucosal form.
In order to analyze the membrane antigens obtained from L. (V.)
braziliensis, the 2D-SDS-PAGE combined with Western blotting wasTable 3
Comparison of EIA-IgG, DS, and the MST of patients with skin lesions referred to LEPAC/
UEM for laboratory diagnosis of ACL in the 2010–2011 period.
DS MST EIA-IgG Total
Positive Negative
Positive Positive 8 1 9
(n = 14) Negative 1 0 1
ND 3 1 4
Negative Positive 4 3 7
(n = 68) Negative 2 28 30
ND 8 23 31
ND Positive 0 1 1
(n = 3) Negative 0 1 1
ND 1 0 1
Total 27 58 85
ND, not done.carried out. Only the serum from the ACL patient showed reactivity,
and no reactivity was observed using serum from healthy individuals
and a patient with Chagas disease, as expected. However, only a
component with apparent molecular weight of 48–56 kDa reacted
with serum from patients with ACL. The 36 kDa component may not
have been detected because of the amount of antigen used (15 μg). In
spite of its complexity, this assay can be used to improve the
characterization of the proteins, providing information about their
molecular weight and pI. Therefore, when combined with mass
spectrometry, this assay can identify a particular protein.
Althoughwe obtained good sensitivity and speciﬁcity, especially in
relation to the group of patients with ACL and healthy individuals, the
antigen used also showed cross-reactivity with serum from patients
with Chagas disease. This cross-reactivity may be due to the use of a
mixture of 36- and 48–56-kDa proteins, which at ﬁrst was
satisfactory. However, after the 2D-SDS-PAGE, we observed that the
sera of healthy individuals and patients with Chagas did not react with
the 36-kDa protein (data not shown). Perhaps if we had chosen to use
only the 48–56-kDa proteins, the speciﬁcity would have been higher.
Despite this limitation, this study makes an important contribution to
the diagnosis of patients with cutaneous leishmaniasis.
The membrane antigens obtained and tested by EIA showed good
sensitivity and speciﬁcity. These data indicate that the EIA-IgG can be
used in the diagnosis of ACL, as well as in seroepidemiological surveys
and follow-up of patients with clinical cure. Further studies are
needed to characterize the antigens chemically, and to obtain only the
components recognized by the sera from ACL patients based on their
molecular weight and isoelectric point, thus minimizing the possibil-
ity of cross-reactivity. It is also necessary to establish the stability of
this antigen, i.e., to determine the expiration time and storage
conditions. In ongoing experiments, we will reﬁne these analyses by
using spectrometry to better characterize the antigen.Acknowledgments
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